We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Genedata Releases ToxPedia™ for Systems Toxicology

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Genedata announces the release of Genedata ToxPedia™, a computational solution supporting organizations to adopt systems toxicology for drug safety prediction.

According to Genedata, systems toxicology promises to reduce costly failures in the late stages of drug development and is attracting interest from pharmaceutical companies as well as drug safety regulators.

To gain the greatest benefit from systems toxicology, scientists need to integrate toxicogenomic data with conventional toxicological end points. This integration can enable a systematic search for clinically relevant molecular biomarkers that can be used to predict a compound’s toxicity profile, before clinical trials are initiated.

ToxPedia supports a data driven approach to systems toxicology. The system can enable biomarker identification based on an integrated analysis of toxicogenomic data, namely of high throughput transcriptomics, proteomics and metabolomics data, with conventional toxicological end points.

The ToxPedia system is built on Genedata Expressionist® platform and has been expanded by Genedata’s professional services team in close collaboration with scientists from pharmaceutical organizations.

The system is designed to address the specific requirements of systems toxicology. Tight integration with all major high throughput technology platforms, coupled with data quality assessment tools, enables ToxPedia to achieve the standards in data quality evaluation. Ultimately, the goal is that ToxPedia supports the standardization and automation of the entire systems toxicology workflow from the initial sample gathering stage through to final study reporting phases, and addresses compliancy aims such as 21 CFR Part 11 guidelines.

Genedata also collaborates actively with research consortia focused on biomarker discovery, including the consortia InnoMed, NewGeneris, and INCA.

“In collaboration with leading scientists in the pharmaceutical industry as well as in academia, we have developed a state-of-the-art computational system for the emerging field of systems toxicology”, explained Dr. Othmar Pfannes, CEO, Genedata AG.